Email this article 
Ph-positive and BCR::ABL1-like acute lymphoblastic leukemia in children
- Authors: Valiev T.T.1,2,3
-
Affiliations:
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
- Issue: Vol 21, No 1 (2026)
- Pages: 77-84
- Section: RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSIS AND TREATMENT CHOICE
- Published: 23.03.2026
- URL: https://oncohematology.eco-vector.com/ongm/article/view/1091
- DOI: https://doi.org/10.17650/1818-8346-2026-21-1-77-84
- ID: 1091
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
In spite of success in pediatric acute lymphoblastic leukemia treatment, there are disease variants, where survival rates significant lower. Such unfavorable rare examples may include Ph-positive and BCR::ABL1-like acute lymphoblastic leukemia. Complex molecular and genetic diagnosis, make use substantially full range of methods (including in some cases next generation sequencing) allow correct diagnosis and make indications for targeted drugs – ruxolitinib in cases of JAK / STAT activation or dasatinib, if ABL1-kinase activated. Intensive chemotherapy with targeted drugs increased treatment effectiveness and admit withdraw from previously obligatory option – allogeneic hematopoietic stem cell transplantation. Nevertheless, for clinical recommendations in BCR::ABL1-like acute lymphoblastic leukemia treatment it is necessary to combine core facilities experience and cooperative studies.
About the authors
T. T. Valiev
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University);Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Author for correspondence.
Email: timurvaliev@mail.ru
ORCID iD: 0000-0002-1469-2365
Pediatric Oncology and Hematology Research Institute, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation, 23 Kashirskoe Shosse, Moscow 115522; Build. 2, 8 Trubetskaya St., Moscow 119048; Build. 1, 2 / 1 Barrikadnaya St., Moscow 125993References
- Stary J., Zimmermann M., Campbell M. et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 2014;32(3):174–84. doi: 10.1200/JCO.2013.48.6522
- Acute leukemias (hematologic malignancies). Eds.: S.H. Faderl, H.M. Kantarjian, E. Estey. 2nd edn. Springer, 2021. P. 289.
- Kowalczyk J.R., Zawitkowska J., Lejman M. et al. Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial. Am J Hematol 2019;94(11): E307–10. doi: 10.1002/ajh.25619
- Aricò M., Schrappe M., Hunger S.P. et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010;28(31):4755–61. doi: 10.1200/JCO.2010.30.1325
- Aricò M., Valsecchi M.G., Camitta B. et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342(14):998–1006. doi: 10.1056/NEJM200004063421402
- Ganguly S., Sasi A., Pushpam D. et al. Philadelphia chromosome positive and Philadelphia-like acute lymphoblastic leukemia in children and adolescents: current management, controversies and emerging concepts. Indian J Pediatr 2024;91(1):37–46. doi: 10.1007/s12098-023-04782-8
- Schultz K.R., Carroll A., Heerema N.A. et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia 2014;28(7):1467–71. doi: 10.1038/leu.2014.30
- Shen S., Chen X., Cai J. et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol 2020;6(3):358–66. doi: 10.1001/jamaoncol.2019.5868
- Pui C.H., Campana D., Sandlund J.T. et al. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. Ann Hematol 2011;90(suppl 1):S61–3.
- Slayton W.B., Schultz K.R., Kairalla J.A. et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J Clin Oncol 2018;36(22):2306–14. doi: 10.1200/JCO.2017.76.7228
- Foà R., Bassan R., Vitale A. et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med 2020;383(17):1613–23. doi: 10.1056/NEJMoa2016272
- Roberts K.G., Li Y., Payne-Turner D. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371(11):1005–15. doi: 10.1056/NEJMoa1403088
- Roberts K.G., Gu Z., Payne-Turner D. et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol 2017;35(4): 394–401. doi: 10.1200/JCO.2016.69.0073
- Jain S., Abraham A. BCR-ABL1-like B-acute lymphoblastic leukemia/lymphoma: a comprehensive review. Arch Pathol Lab Med 2020;144(2):150–5. doi: 10.5858/arpa.2019-0194-RA
- Cario G., Leoni V., Conter V. et al. BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. Haematologica 2020;105(9):2200–4. doi: 10.3324/haematol.2018.207019
- Alghandour R., Sakr D.H., Shaaban Y. Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article. Ann Hematol 2023;102(6):1287–300. doi: 10.1007/s00277-023-05241-2
Supplementary files
